Our Location

304 North Cardinal St.
Dorchester Center, MA 02124

Elopag-50mg-Eltrombopag

Product Name: Elopag

Strength: 50mg

Volume: 28 tablet

To order: +8801304498958

Description

Package Insert of Elopag-50mg-Eltrombopag

Description | Elopag-50mg-Eltrombopag

Elopag-50mg-Eltrombopag is a medication used to treat low blood platelet counts in adults with chronic immune thrombocytopenia (ITP), a condition that can cause unusual bleeding or bruising due to an abnormally low number of platelets in the blood. It has also been approved for treating thrombocytopenia in patients with chronic hepatitis C, allowing them to initiate and maintain interferon-based therapy. Elopag-50mg is used after a splenectomy and other medications have not worked well enough. (1)

Indications for Elopag-50mg-Eltrombopag

Elopag-50mg is indicated for the treatment of:

  • Chronic idiopathic thrombocytopenic purpura (ITP) in adults and children 1 year of age and older
  • Primary immune thrombocytopenia (PITP) in adults and children 1 year of age and older
  • Chronic hepatitis C (CHC)-associated thrombocytopenia in adults
  • Refractory severe aplastic anemia (SAA) in adults

Elopag-50mg can also be used in combination with other medications to treat certain types of leukemia. (2)

 Mechanism of Action of Elopag-50mg-Eltrombopag

Elopag-50mg is a small-molecule TPO-receptor agonist that interacts with the human TPO-receptor. It stimulates STAT and JAK phosphorylation. It does not activate the AKT pathway, unlike recombinant TPO or romiplostim. When given to patients with aplastic anemia, it increases other lineages besides platelet count, suggesting it enhances the effect of TPO in vivo or has a yet-uncovered mechanism of action.

Eltrombopag stimulates the bone marrow to produce more platelets, helping prevent bleeding problems in those with thrombocytopenia. It is used in the first-line treatment of severe aplastic anemia in adults and children. (3)

Dosage and administration of Elopag-50mg-Eltrombopag:

The recommended dosage for Elopag 50mg may vary depending on individual patient factors and the specific condition being treated. It is crucial to follow the guidance provided by your healthcare professional. Generally, the dosage instructions for Elopag 50mg are as follows:

  1. Chronic immune thrombocytopenia (ITP):
    • Starting dose: The typical initial dose is 50mg once daily.
    • Titration: Based on your platelet count response, your healthcare provider may adjust the dosage every 2 weeks in increments of 25mg or 50mg, up to a maximum dose of 75mg once daily.
  2. Chronic hepatitis C-associated thrombocytopenia:
    • Starting dose: The usual starting dose is 50mg once daily.
    • Titration: Depending on your platelet count response, your healthcare provider may adjust the dosage every 2 weeks in increments of 25mg or 50mg, up to a maximum dose of 100mg once daily.

It is essential to strictly adhere to your prescribed dosage and follow the instructions provided by your healthcare professional. They will monitor your platelet counts regularly and make any necessary adjustments to ensure optimal treatment outcomes.

Never adjust your Elopag 50mg dosage without consulting your healthcare provider, as it may affect the effectiveness and safety of the medication. If you have any questions or concerns regarding your dosage or treatment plan, always seek guidance from your healthcare professional for personalized advice. (4)

Side Effects of Eltrombopag

A medicine may cause some unwanted side effects, which may require medical attention. Common side effects include bloating, swelling, body pain, chills, cough, difficulty breathing, fever, headache, loss of voice, chest pain, groin pain, chest pain, tingling, difficulty breathing, unusual tiredness, weight gain, and yellow eyes or skin. Less common side effects include bladder pain, blindness, blurred vision, bruising, burning, itching, numbness, diarrhea, and general discomfort. These side effects may go away during treatment as the body adjusts to the medicine. Health care professionals may also provide information on preventing or reducing these side effects. If any side effects persist or are bothersome, consult with your doctor if you have any questions or concerns. (5)

 Eltrombopag Price

The price of eltrombopag can vary depending on the dosage form, the number of tablets, and your insurance coverage. However, it can be expensive, costing several thousand dollars per month.

But Elopag-50mg is cheaper than any other version of Eltrombopag and it has similar efficiency. To order  Elopag-50mg contact with us.

Approval of Eltrombopag by FDA

Eltrombopag is approved by the US Food and Drug Administration (FDA) for the treatment of:

  • Chronic idiopathic thrombocytopenic purpura (ITP) in adults and children 1 year of age and older
  • Primary immune thrombocytopenia (PITP) in adults and children 1 year of age and older
  • Chronic hepatitis C (CHC)-associated thrombocytopenia in adults
  • Refractory severe aplastic anemia (SAA) in adults

Eltrombopag was first approved by the FDA in 2008 for the treatment of ITP. It was subsequently approved for the treatment of PITP in 2011, CHC-associated thrombocytopenia in 2013, and SAA in 2015.  (6)

Eltrombopag in Dengue

Eltrombopag, a thrombopoietin receptor agonist, is being explored as a potential treatment for dengue fever, a mosquito-borne viral infection that can cause severe bleeding. It works by stimulating platelet production in the bone marrow, increasing platelet counts and reducing bleeding risk. Clinical trials have shown promising results, with one trial showing erombopaglt’s effectiveness in increasing platelet counts and reducing bleeding risk. However, more research is needed to confirm its safety and efficacy.Elopag-50mg is not currently approved by the US FDA for dengue fever treatment, but it is being used in countries where it is available due to the lack of other effective treatments. Side effects include diarrhea, nausea, headache, liver damage, and heart problems.

Eltrombopag in Aplastic Anemia

Elopag-50mg is a thrombopoietin receptor agonist (TPO-RA) that is used to treat aplastic anemia, a rare blood disorder that causes the bone marrow to produce too few blood cells. It works by stimulating the production of platelets in the bone marrow. This can help to increase platelet counts and reduce the risk of bleeding in patients with aplastic anemia.

Eltrombopag Myelodysplastic Syndrome

Clinical trials have evaluated the safety and efficacy of Elopag-50mg in treating MDS patients. However, the results have been mixed, with some trials showing it increases platelet counts but doesn’t improve overall survival. Another trial showed it reduces platelet transfusion need, but more research is needed. Elopag-50mg is not approved by the FDA for MDS treatment, but it is used in some countries due to the lack of other effective treatments. It is generally well-tolerated but can cause side effects like diarrhea, nausea, fatigue, headache, cough, rash, liver damage, heart problems, bleeding, and allergic reactions.

Eltrombopag Clinical trials

Eltrombopag has been studied in a number of clinical trials, including trials in patients with ITP, PITP, CHC-associated thrombocytopenia, refractory SAA, and dengue fever. Results from these trials have shown that eltrombopag is an effective and safe treatment for these conditions.

Here are some examples of eltrombopag clinical trials:

  • ITP: A Phase III clinical trial in patients with ITP showed that Elopag-50mgwas more effective than placebo in increasing platelet counts and reducing the risk of bleeding.
  • PITP: A Phase III clinical trial in patients with PITP showed that Elopag-50mg was more effective than placebo in increasing platelet counts and reducing the risk of bleeding.
  • CHC-associated thrombocytopenia: A Phase III clinical trial in patients with CHC-associated thrombocytopenia showed that Elopag-50mg was more effective than placebo in increasing platelet counts and reducing the risk of bleeding.
  • Refractory SAA: A Phase II clinical trial in patients with refractory SAA showed that Elopag-50mgincreased platelet counts to safe levels in 75% of patients.
  • Dengue fever: A Phase II clinical trial in patients with severe dengue fever showed that Elopag-50mg was effective in increasing platelet counts and reducing the risk of bleeding.

Eltrombopag brand name

The brand name of eltrombopag is Promacta. It is available as a tablet and oral suspension.

Promacta is manufactured by Novartis Pharmaceuticals Corporation and is marketed in the United States and Canada. It is also marketed in other countries under the brand name Revolade.

See our other Products Elbonix-25, Avalet-20mg, Palbonix100/125mg, Ventoxen-100mg, Ibruxen-140mg.

FAQs about Elopag-50mg:

Q: What is Elopag-50mg-Eltrombopag?

A: Elopag-50mg-Eltrombopag is a medication containing the active ingredient Eltrombopag. It is prescribed to stimulate platelet production in individuals with conditions such as chronic immune thrombocytopenia (ITP) or chronic hepatitis C-associated thrombocytopenia.

Q: How does Elopag-50mg-Eltrombopag work?

A: Elopag-50mg-Eltrombopag works by interacting with the body’s natural processes to stimulate the production of platelets in the bone marrow. It helps increase platelet counts, reducing the risk of bleeding and improving clotting ability.

Q:

What is the recommended dosage of Elopag-50mg-Eltrombopag?
The usual starting dosage of Elopag-50mg-Eltrombopag is 50mg once daily. However, the dosage may be adjusted by your healthcare provider based on your response and condition. It is important to follow the dosage instructions provided by your healthcare professional.
What is Elopag-50mg-Eltrombopag?
Elopag-50mg-Eltrombopag is a medication containing the active ingredient eltrombopag. It is prescribed to stimulate platelet production in individuals with conditions such as chronic immune thrombocytopenia (ITP) or chronic hepatitis C-associated thrombocytopenia.

A: The usual starting dosage of Elopag-50mg-Eltrombopag is 50mg once daily. However, the dosage may be adjusted by your healthcare provider based on your response and condition. It is important to follow the dosage instructions provided by your healthcare professional.

Q: How long does it take for Elopag-50mg-Eltrombopag to show results?

A: The timeframe for experiencing noticeable results may vary among individuals. Some patients may see an improvement in platelet counts within a few weeks of starting Elopag-50mg-Eltrombopag, while others may require a longer duration. It is essential to continue taking the medication as prescribed and follow up with your healthcare provider for monitoring and adjustments.

Q: Are there any side effects associated with Elopag-50mg-Eltrombopag?

A: Like any medication, Elopag-50mg-Eltrombopag may have potential side effects. Common side effects may include nausea, headache, fatigue, muscle or joint pain, and changes in liver function tests. However, not everyone experiences these side effects. It is important to discuss any concerns or unexpected symptoms with your healthcare provider.

Q: Can I take other medications along with Elopag-50mg-Eltrombopag?

A: It is important to inform your healthcare provider about all medications, supplements, or herbal products you are taking. Some medications may interact with Elopag-50mg-Eltrombopag, potentially affecting its effectiveness or increasing the risk of side effects. Your healthcare provider will assess the compatibility and guide you on any necessary precautions.

Contact us for ordering medicines

Whats app and WeChat: +8801304498958

Reviews

There are no reviews yet.

Be the first to review “Elopag-50mg-Eltrombopag”